These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 25868746)

  • 1. Discovery of novel spiro 1,3,4-thiadiazolines as potent, orally bioavailable and brain penetrant KSP inhibitors.
    Mansoor UF; Angeles AR; Dai C; Yang L; Vitharana D; Basso AD; Gray K; Tang H; Liu M; Liang L; Allbritton O; Siddiqui MA
    Bioorg Med Chem; 2015 May; 23(10):2424-34. PubMed ID: 25868746
    [TBL] [Abstract][Full Text] [Related]  

  • 2. SCH 2047069, a novel oral kinesin spindle protein inhibitor, shows single-agent antitumor activity and enhances the efficacy of chemotherapeutics.
    Basso AD; Liu M; Dai C; Gray K; Nale L; Tevar S; Lee S; Liang L; Ponery A; Yaremko B; Smith E; Tang H; Sheth PR; Siddiqui MA; Hicklin DJ; Kirschmeier P
    Mol Cancer Ther; 2010 Nov; 9(11):2993-3002. PubMed ID: 20978164
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Discovery of allosteric inhibitors of kinesin spindle protein (KSP) for the treatment of taxane-refractory cancer: MK-0731 and analogs.
    Cox CD; Garbaccio RM
    Anticancer Agents Med Chem; 2010 Nov; 10(9):697-712. PubMed ID: 21235439
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Novel ATP-competitive kinesin spindle protein inhibitors.
    Parrish CA; Adams ND; Auger KR; Burgess JL; Carson JD; Chaudhari AM; Copeland RA; Diamond MA; Donatelli CA; Duffy KJ; Faucette LF; Finer JT; Huffman WF; Hugger ED; Jackson JR; Knight SD; Luo L; Moore ML; Newlander KA; Ridgers LH; Sakowicz R; Shaw AN; Sung CM; Sutton D; Wood KW; Zhang SY; Zimmerman MN; Dhanak D
    J Med Chem; 2007 Oct; 50(20):4939-52. PubMed ID: 17725339
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Antitumor activity of a kinesin inhibitor.
    Sakowicz R; Finer JT; Beraud C; Crompton A; Lewis E; Fritsch A; Lee Y; Mak J; Moody R; Turincio R; Chabala JC; Gonzales P; Roth S; Weitman S; Wood KW
    Cancer Res; 2004 May; 64(9):3276-80. PubMed ID: 15126370
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Discovery of tetrahydro-beta-carbolines as inhibitors of the mitotic kinesin KSP.
    Liu F; Yu LQ; Jiang C; Yang L; Wu WT; You QD
    Bioorg Med Chem; 2010 Jun; 18(12):4167-77. PubMed ID: 20537544
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Mechanism of inhibition of human KSP by monastrol: insights from kinetic analysis and the effect of ionic strength on KSP inhibition.
    Luo L; Carson JD; Dhanak D; Jackson JR; Huang PS; Lee Y; Sakowicz R; Copeland RA
    Biochemistry; 2004 Dec; 43(48):15258-66. PubMed ID: 15568818
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Developments of kinesin spindle protein inhibitors as antitumor agents based on the five-membered heterocycle scaffolds.
    Zhao GD; Wan RZ; Liu ZP
    Curr Med Chem; 2014; 21(23):2691-701. PubMed ID: 24606497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Progress on kinesin spindle protein inhibitors as anti-cancer agents.
    Zhang Y; Xu W
    Anticancer Agents Med Chem; 2008 Aug; 8(6):698-704. PubMed ID: 18690830
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of KSP Inhibitors as Anti-cancer Therapeutics: An Update.
    Chamariya R; Suvarna V
    Anticancer Agents Med Chem; 2022; 22(14):2517-2538. PubMed ID: 35043768
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, biological evaluation and molecular docking studies of flavone and isoflavone derivatives as a novel class of KSP (kinesin spindle protein) inhibitors.
    Dong JJ; Li QS; Liu ZP; Wang SF; Zhao MY; Yang YH; Wang XM; Zhu HL
    Eur J Med Chem; 2013; 70():427-33. PubMed ID: 24184776
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibitors of kinesin Eg5: antiproliferative activity of monastrol analogues against human glioblastoma cells.
    Müller C; Gross D; Sarli V; Gartner M; Giannis A; Bernhardt G; Buschauer A
    Cancer Chemother Pharmacol; 2007 Feb; 59(2):157-64. PubMed ID: 16703323
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Targeting the kinesin spindle protein: basic principles and clinical implications.
    Sarli V; Giannis A
    Clin Cancer Res; 2008 Dec; 14(23):7583-7. PubMed ID: 19047082
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The discovery of Polo-like kinase 4 inhibitors: design and optimization of spiro[cyclopropane-1,3'[3H]indol]-2'(1'H).ones as orally bioavailable antitumor agents.
    Sampson PB; Liu Y; Patel NK; Feher M; Forrest B; Li SW; Edwards L; Laufer R; Lang Y; Ban F; Awrey DE; Mao G; Plotnikova O; Leung G; Hodgson R; Mason JM; Wei X; Kiarash R; Green E; Qiu W; Chirgadze NY; Mak TW; Pan G; Pauls HW
    J Med Chem; 2015 Jan; 58(1):130-46. PubMed ID: 24867403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Potentiation of kinesin spindle protein inhibitor-induced cell death by modulation of mitochondrial and death receptor apoptotic pathways.
    Vijapurkar U; Wang W; Herbst R
    Cancer Res; 2007 Jan; 67(1):237-45. PubMed ID: 17210704
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Mechanism of inhibition of human KSP by ispinesib.
    Lad L; Luo L; Carson JD; Wood KW; Hartman JJ; Copeland RA; Sakowicz R
    Biochemistry; 2008 Mar; 47(11):3576-85. PubMed ID: 18290633
    [TBL] [Abstract][Full Text] [Related]  

  • 17. K858, a novel inhibitor of mitotic kinesin Eg5 and antitumor agent, induces cell death in cancer cells.
    Nakai R; Iida S; Takahashi T; Tsujita T; Okamoto S; Takada C; Akasaka K; Ichikawa S; Ishida H; Kusaka H; Akinaga S; Murakata C; Honda S; Nitta M; Saya H; Yamashita Y
    Cancer Res; 2009 May; 69(9):3901-9. PubMed ID: 19351824
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Kinesin spindle protein (KSP) inhibitors. Part 1: The discovery of 3,5-diaryl-4,5-dihydropyrazoles as potent and selective inhibitors of the mitotic kinesin KSP.
    Cox CD; Breslin MJ; Mariano BJ; Coleman PJ; Buser CA; Walsh ES; Hamilton K; Huber HE; Kohl NE; Torrent M; Yan Y; Kuo LC; Hartman GD
    Bioorg Med Chem Lett; 2005 Apr; 15(8):2041-5. PubMed ID: 15808464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Mcl-1 stability determines mitotic cell fate of human multiple myeloma tumor cells treated with the kinesin spindle protein inhibitor ARRY-520.
    Tunquist BJ; Woessner RD; Walker DH
    Mol Cancer Ther; 2010 Jul; 9(7):2046-56. PubMed ID: 20571074
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Thermodynamics of nucleotide and inhibitor binding to wild-type and ispinesib-resistant forms of human kinesin spindle protein.
    Sheth PR; Basso A; Duca JS; Lesburg CA; Ogas P; Gray K; Nale L; Mannarino AF; Prongay AJ; Le HV
    Biochemistry; 2009 Nov; 48(46):11045-55. PubMed ID: 19824700
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.